文献速递临床试验与 GCP

低强度脉冲超声治疗病毒性肺炎的疗效:随机对照试验研究方案

Efficacy of low-intensity pulsed ultrasound for the treatment of viral pneumonia: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-06-09

本研究为随机对照试验方案,拟纳入60例临床确诊病毒性肺炎住院患者,分为干预组(低强度脉冲超声刺激)、对照组(无效刺激)和自身对照组(超声刺激区与非刺激区对比)。主要结局为计算机断层扫描上肺部炎症吸收消散程度的差异,次要结局包括超声图像炎症变化、肺功能、血气分析、指尖动脉血氧饱和度、血清炎症因子水平、排痰量、肺部啰音消失时间、肺炎状态评分和肺炎病程,并记录不良事件。

要点

  • 拟纳入60例临床确诊病毒性肺炎住院患者,分干预组、对照组和自身对照组。
  • 主要结局为CT上肺部炎症吸收消散程度的差异。
  • 次要结局包括超声图像炎症变化、肺功能、血气分析、指尖血氧饱和度等。

核心结论

  • 低强度脉冲超声作为一种新治疗方法,可能成为病毒性肺炎治疗的重大进展。

研究设计与样本

  • 随机对照试验方案,拟纳入60例临床确诊病毒性肺炎住院患者,分为干预组(低强度脉冲超声刺激)、对照组(无效刺激)和自身对照组(超声刺激区与非刺激区对比)。

主要发现

  • 主要结局为计算机断层扫描上肺部炎症吸收消散程度的差异。
  • 次要结局包括超声图像上肺部炎症变化、肺功能、血气分析、指尖动脉血氧饱和度、血清炎症因子水平、排痰量、肺部啰音消失时间、肺炎状态评分和肺炎病程。
  • 将记录不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Viral pneumonia has always been a problem faced by clinicians because of its insidious onset, strong infectivity, and lack of effective drugs. Patients with advanced age or underlying diseases may experience more severe symptoms and are prone to severe ventilation dysfunction. Reducing pulmonary inflammation and improving clinical symptoms is the focus of current treatment. Low-intensity pulsed ultrasound (LIPUS) can mitigate inflammation and inhibit edema formation. We aimed to investigate the efficacy of therapeutic LIPUS in improving lung inflammation in hospitalized patients with viral pneumonia. METHODS: Sixty eligible participants with clinically confirmed viral pneumonia will be assigned to either (1) intervention group (LIPUS stimulus), (2) control group (null stimulus), or (3) self-control group (LIPUS stimulated areas versus non-stimulated areas). The primary outcome will be the difference in the extent of absorption and dissipation of lung inflammation on computed tomography. Secondary outcomes include changes in lung inflammation on ultrasonography images, pulmonary function, blood gas analysis, fingertip arterial oxygen saturation, serum inflammatory factor levels, the sputum excretion volume, time to the disappearance of pulmonary rales, pneumonia status score, and course of pneumonia. Adverse events will be recorded. DISCUSSION: This study is the first clinical study of the efficacy of therapeutic LIPUS in the treatment of viral pneumonia. Given that the current clinical recovery mainly depends on the body's self-limiting and conventional symptomatic treatment, LIPUS, as a new therapy method, might be a major advance in the treatment of viral pneumonia. TRIAL REGISTRATION: ChiCTR2200059550 Chinese Clinical Trial Registry, May 3, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li X, Li W, Sun L, et al. Efficacy of low-intensity pulsed ultrasound for the treatment of viral pneumonia: study protocol for a randomized controlled trial. Trials. 2023. PMID: 37296443. doi:10.1186/s13063-023-07382-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。